A third new Alzheimer's drug, donanemab, is set for FDA approval, marking a significant step in slowing the progression of the disease. However, these treatments, which work best in the disease's early stages, may not suffice for patients with advanced Alzheimer's.
Donanemab: A Promising Step Forward in Early-Stage Alzheimer's Treatment
Neuroscience News - 17 Jul 2023 21:21
A third new Alzheimer's drug, donanemab, is set for FDA approval, marking a significant step in slowing the progression of the disease. However, these treatments, which work best in the disease's early stages, may not suffice for patients with advanced Alzheimer's.
Share this Article
Recommended